Marc S Raab

Teclistamab-based induction regimens have demonstrated efficacy in patients with newly diagnosed multiple myeloma, according to phase 2 trial results presented by @raabms.bsky.social at #IMIS25. shorturl.at/EEQSh #mmsm #ims2025

Major Regulatory Milestone in MM: In response to an application by I2TEAMM and IMFmyeloma, the European Medicines Agency has officially endorsed MRD as an early endpoint in clinical trials for Myeloma. This marks a transformative step forward in drug development !! @vincentrk.bsky.social

📣 We are excited to announce the 10th Heidelberg Myeloma Workshop
 
Join us on April 25–26, 2025, as international & local experts share the latest advancements in multiple myeloma research.
#mmsm

✅ CME-certified
🔗 Speaker line-up & registration 👇🏼
myelomaworkshop.de

QS Ranking by Subject: First Place in Life Sciences and Medicine – Heidelberg University takes top positions Germany-wide
www.uni-heidelberg.de/en/newsroom/...

Prof Martin Kaiser (@mymkaiser.bsky.social) who led the study, says: “We would like all myeloma patients to be able to access the newer diagnostic tests which enable clinicians to group individual patients based on their risk profile and provide treatment that is tailored to their needs.”

NEW 📰: Research led by ICR scientists and @universityofleeds.bsky.social has shown that #BloodCancer myeloma patients who carry two of more genetic abnormalities – called ‘double hit’ #Myeloma - are at more than twice the risk of their disease progressing early.

Great teamwork with co-lead Niels Weinhold (@HDMyeloma) and a fantastic effort led by Raphael Lutz, Alexandra Poos, Llorenç Solé Boldo, Lukas John, and many others. Grateful for such an incredible team! 👏 #TeamScience 2/2

How does multiple myeloma progress? In our latest Science Immunology cover story, we reveal how myeloma cells breaking through bone trigger dangerous diversity. This arises from bidirectional interactions with the immune system, fueling disease evolution. scim.ag/4hMrLHs 1/2